Loading…
A LARGE QUANTITY OF CD3− CD19− CD16− LYMPHOCYTES IN MALIGNANT PLEURAL EFFUSION FROM A PATIENT WITH RECURRENT CHOLANGIO CELL CARCINOMA
Tumor infiltrating lymphocytes (TILs) are candidates for adoptive cellular immunotherapy. Here we report on a patient whose TILs presented unusual lymphocyte antigens. Pleural effusions were collected from a 47-year-old man with recurrent cholangio cell carcinoma and malignant effusion. Effusion- as...
Saved in:
Published in: | Immunological investigations 2002-01, Vol.31 (2), p.121-135 |
---|---|
Main Authors: | , , , , , , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | cdi_FETCH-LOGICAL-c386t-1d3c84bfee1d05d02283f23a271f0c917af40280f19dd3d1d1a674479ee72d2a3 |
---|---|
cites | cdi_FETCH-LOGICAL-c386t-1d3c84bfee1d05d02283f23a271f0c917af40280f19dd3d1d1a674479ee72d2a3 |
container_end_page | 135 |
container_issue | 2 |
container_start_page | 121 |
container_title | Immunological investigations |
container_volume | 31 |
creator | Onishi, Hideya Morisaki, Takashi Kuga, Hirotaka Katano, Mitsuo Doi, Fukashi Uchiyama, Akihiko Sugitani, Atsushi Wada, Junji Chijiiwa, Kazuo Tanaka, Masao |
description | Tumor infiltrating lymphocytes (TILs) are candidates for adoptive cellular immunotherapy. Here we report on a patient whose TILs presented unusual lymphocyte antigens. Pleural effusions were collected from a 47-year-old man with recurrent cholangio cell carcinoma and malignant effusion. Effusion- associated lymphocytes (EALs) were separated by Ficoll-Hypaque gradient, and the EAL phenotype was determined by flow cytometry. The percentage of positive cells was determined for each lymphocyte-related differentiation antigen. The percentages of CD3+, CD19+, and CD16+ lymphocyte subpopulations among EALs were 20%, 7%, and 3%, respectively. Nearly 70% of EALs were CD3− CD19− CD56− CD16−cells. The phenotypes of peripheral blood lymphocytes (PBLs) collected simultaneously from the patient's peripheral blood were CD3+ (52%), CD19+ (20%), and CD16+ (20%).When EALs were cultured in medium without pleural effusion, T cell-related antigens, but not B cell- or natural killer (NK) cell-related antigens, were newly expressed on EALs, and this expression reached a plateau after 48 h in culture. The proportions of CD3+, CD19+, and CD16+ cells were 69%, 7%, and 3%, respectively. However, when EALs were cultured in medium with pleural effusion, increased expression of T cell-related antigens was not observed; the proportions of CD3+, CD19+, and CD16+ cells were 16%, 6%, and 1%, respectively. Neither total cell numbers nor cellular viability of EALs changed significantly after in-vitro culture, suggesting that significant proliferation or death of EALs did not occur during the culture period. Co-culture of the patient's PBLs with autologous pleural effusion for 96 h did not alter the expression of lymphocyte-related antigens on the PBLs. These results indicate that expression of T cell-related antigens, but not B cell- or NK cell-related antigens, on EALs was blocked temporarily by the malignant pleural effusion. This is the first report concerning the existence of a large quantity of unclassified lymphocytes in which the T cell-related antigens were reversibly masked in the malignant pleural effusion. |
doi_str_mv | 10.1081/IMM-120004803 |
format | article |
fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmed_primary_12148948</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>71955780</sourcerecordid><originalsourceid>FETCH-LOGICAL-c386t-1d3c84bfee1d05d02283f23a271f0c917af40280f19dd3d1d1a674479ee72d2a3</originalsourceid><addsrcrecordid>eNp1kMGK2zAQhkVp6aZpj70WnXpzq5HsWD4K104Esp16bUpORmvJbBYn3pUTyr5Bobc-4j7JOiS09LCnn2G--Rk-hD4C-QKEw1eZZR5QQojPCXuFZhAw6vkM4DWaEc6pR4BFV-jdON5NEAsW0Vt0BRR8Hvl8hn4LrES5TPD3WuSVrDa4SHH8jT39-jMFRJdcnFJtsvWqiDdVco1ljjOh5DKfrvBaJXUpFE7StL6WRY7TssiwwGtRyWTa_5DVCpdJXJflaYxXhRL5UhY4TpTCsShjmReZeI_edLof7YdLzlGdJlW88lSxlLFQXsv44uCBYS33bzprwZDAEEo56yjTNISOtBGEuvMJ5aSDyBhmwIBehL4fRtaG1FDN5ujzuffeDQ9HOx6a3XZsbd_rvR2OYxNCFAThpHOOvDPYumEcne2ae7fdaffYAGlO9pvJfvPX_sR_uhQfb3bW_KMvuieAn4HtvhvcTv8cXG-ag37sB9c5vW-3Y8Ne6g7_O721uj_cttrZ5m44uv0k7IWvngGZIpsm</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>71955780</pqid></control><display><type>article</type><title>A LARGE QUANTITY OF CD3− CD19− CD16− LYMPHOCYTES IN MALIGNANT PLEURAL EFFUSION FROM A PATIENT WITH RECURRENT CHOLANGIO CELL CARCINOMA</title><source>Taylor and Francis:Jisc Collections:Taylor and Francis Read and Publish Agreement 2024-2025:Medical Collection (Reading list)</source><creator>Onishi, Hideya ; Morisaki, Takashi ; Kuga, Hirotaka ; Katano, Mitsuo ; Doi, Fukashi ; Uchiyama, Akihiko ; Sugitani, Atsushi ; Wada, Junji ; Chijiiwa, Kazuo ; Tanaka, Masao</creator><creatorcontrib>Onishi, Hideya ; Morisaki, Takashi ; Kuga, Hirotaka ; Katano, Mitsuo ; Doi, Fukashi ; Uchiyama, Akihiko ; Sugitani, Atsushi ; Wada, Junji ; Chijiiwa, Kazuo ; Tanaka, Masao</creatorcontrib><description>Tumor infiltrating lymphocytes (TILs) are candidates for adoptive cellular immunotherapy. Here we report on a patient whose TILs presented unusual lymphocyte antigens. Pleural effusions were collected from a 47-year-old man with recurrent cholangio cell carcinoma and malignant effusion. Effusion- associated lymphocytes (EALs) were separated by Ficoll-Hypaque gradient, and the EAL phenotype was determined by flow cytometry. The percentage of positive cells was determined for each lymphocyte-related differentiation antigen. The percentages of CD3+, CD19+, and CD16+ lymphocyte subpopulations among EALs were 20%, 7%, and 3%, respectively. Nearly 70% of EALs were CD3− CD19− CD56− CD16−cells. The phenotypes of peripheral blood lymphocytes (PBLs) collected simultaneously from the patient's peripheral blood were CD3+ (52%), CD19+ (20%), and CD16+ (20%).When EALs were cultured in medium without pleural effusion, T cell-related antigens, but not B cell- or natural killer (NK) cell-related antigens, were newly expressed on EALs, and this expression reached a plateau after 48 h in culture. The proportions of CD3+, CD19+, and CD16+ cells were 69%, 7%, and 3%, respectively. However, when EALs were cultured in medium with pleural effusion, increased expression of T cell-related antigens was not observed; the proportions of CD3+, CD19+, and CD16+ cells were 16%, 6%, and 1%, respectively. Neither total cell numbers nor cellular viability of EALs changed significantly after in-vitro culture, suggesting that significant proliferation or death of EALs did not occur during the culture period. Co-culture of the patient's PBLs with autologous pleural effusion for 96 h did not alter the expression of lymphocyte-related antigens on the PBLs. These results indicate that expression of T cell-related antigens, but not B cell- or NK cell-related antigens, on EALs was blocked temporarily by the malignant pleural effusion. This is the first report concerning the existence of a large quantity of unclassified lymphocytes in which the T cell-related antigens were reversibly masked in the malignant pleural effusion.</description><identifier>ISSN: 0882-0139</identifier><identifier>EISSN: 1532-4311</identifier><identifier>DOI: 10.1081/IMM-120004803</identifier><identifier>PMID: 12148948</identifier><language>eng</language><publisher>England: Informa UK Ltd</publisher><subject>Antigens, CD19 - metabolism ; CD3 Complex - metabolism ; Cholangiocarcinoma - immunology ; Cholangiocarcinoma - therapy ; Humans ; Immunotherapy, Adoptive ; In Vitro Techniques ; Interferon-gamma - biosynthesis ; Lymphocytes, Tumor-Infiltrating - immunology ; Male ; Middle Aged ; Neoplasm Recurrence, Local - immunology ; Neoplasm Recurrence, Local - therapy ; Picibanil - pharmacology ; Pleural Effusion, Malignant - immunology ; Pleural Effusion, Malignant - therapy ; Receptors, IgG - metabolism ; T-Lymphocytes - immunology</subject><ispartof>Immunological investigations, 2002-01, Vol.31 (2), p.121-135</ispartof><rights>2002 Informa UK Ltd All rights reserved: reproduction in whole or part not permitted 2002</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c386t-1d3c84bfee1d05d02283f23a271f0c917af40280f19dd3d1d1a674479ee72d2a3</citedby><cites>FETCH-LOGICAL-c386t-1d3c84bfee1d05d02283f23a271f0c917af40280f19dd3d1d1a674479ee72d2a3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/12148948$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Onishi, Hideya</creatorcontrib><creatorcontrib>Morisaki, Takashi</creatorcontrib><creatorcontrib>Kuga, Hirotaka</creatorcontrib><creatorcontrib>Katano, Mitsuo</creatorcontrib><creatorcontrib>Doi, Fukashi</creatorcontrib><creatorcontrib>Uchiyama, Akihiko</creatorcontrib><creatorcontrib>Sugitani, Atsushi</creatorcontrib><creatorcontrib>Wada, Junji</creatorcontrib><creatorcontrib>Chijiiwa, Kazuo</creatorcontrib><creatorcontrib>Tanaka, Masao</creatorcontrib><title>A LARGE QUANTITY OF CD3− CD19− CD16− LYMPHOCYTES IN MALIGNANT PLEURAL EFFUSION FROM A PATIENT WITH RECURRENT CHOLANGIO CELL CARCINOMA</title><title>Immunological investigations</title><addtitle>Immunol Invest</addtitle><description>Tumor infiltrating lymphocytes (TILs) are candidates for adoptive cellular immunotherapy. Here we report on a patient whose TILs presented unusual lymphocyte antigens. Pleural effusions were collected from a 47-year-old man with recurrent cholangio cell carcinoma and malignant effusion. Effusion- associated lymphocytes (EALs) were separated by Ficoll-Hypaque gradient, and the EAL phenotype was determined by flow cytometry. The percentage of positive cells was determined for each lymphocyte-related differentiation antigen. The percentages of CD3+, CD19+, and CD16+ lymphocyte subpopulations among EALs were 20%, 7%, and 3%, respectively. Nearly 70% of EALs were CD3− CD19− CD56− CD16−cells. The phenotypes of peripheral blood lymphocytes (PBLs) collected simultaneously from the patient's peripheral blood were CD3+ (52%), CD19+ (20%), and CD16+ (20%).When EALs were cultured in medium without pleural effusion, T cell-related antigens, but not B cell- or natural killer (NK) cell-related antigens, were newly expressed on EALs, and this expression reached a plateau after 48 h in culture. The proportions of CD3+, CD19+, and CD16+ cells were 69%, 7%, and 3%, respectively. However, when EALs were cultured in medium with pleural effusion, increased expression of T cell-related antigens was not observed; the proportions of CD3+, CD19+, and CD16+ cells were 16%, 6%, and 1%, respectively. Neither total cell numbers nor cellular viability of EALs changed significantly after in-vitro culture, suggesting that significant proliferation or death of EALs did not occur during the culture period. Co-culture of the patient's PBLs with autologous pleural effusion for 96 h did not alter the expression of lymphocyte-related antigens on the PBLs. These results indicate that expression of T cell-related antigens, but not B cell- or NK cell-related antigens, on EALs was blocked temporarily by the malignant pleural effusion. This is the first report concerning the existence of a large quantity of unclassified lymphocytes in which the T cell-related antigens were reversibly masked in the malignant pleural effusion.</description><subject>Antigens, CD19 - metabolism</subject><subject>CD3 Complex - metabolism</subject><subject>Cholangiocarcinoma - immunology</subject><subject>Cholangiocarcinoma - therapy</subject><subject>Humans</subject><subject>Immunotherapy, Adoptive</subject><subject>In Vitro Techniques</subject><subject>Interferon-gamma - biosynthesis</subject><subject>Lymphocytes, Tumor-Infiltrating - immunology</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Neoplasm Recurrence, Local - immunology</subject><subject>Neoplasm Recurrence, Local - therapy</subject><subject>Picibanil - pharmacology</subject><subject>Pleural Effusion, Malignant - immunology</subject><subject>Pleural Effusion, Malignant - therapy</subject><subject>Receptors, IgG - metabolism</subject><subject>T-Lymphocytes - immunology</subject><issn>0882-0139</issn><issn>1532-4311</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2002</creationdate><recordtype>article</recordtype><recordid>eNp1kMGK2zAQhkVp6aZpj70WnXpzq5HsWD4K104Esp16bUpORmvJbBYn3pUTyr5Bobc-4j7JOiS09LCnn2G--Rk-hD4C-QKEw1eZZR5QQojPCXuFZhAw6vkM4DWaEc6pR4BFV-jdON5NEAsW0Vt0BRR8Hvl8hn4LrES5TPD3WuSVrDa4SHH8jT39-jMFRJdcnFJtsvWqiDdVco1ljjOh5DKfrvBaJXUpFE7StL6WRY7TssiwwGtRyWTa_5DVCpdJXJflaYxXhRL5UhY4TpTCsShjmReZeI_edLof7YdLzlGdJlW88lSxlLFQXsv44uCBYS33bzprwZDAEEo56yjTNISOtBGEuvMJ5aSDyBhmwIBehL4fRtaG1FDN5ujzuffeDQ9HOx6a3XZsbd_rvR2OYxNCFAThpHOOvDPYumEcne2ae7fdaffYAGlO9pvJfvPX_sR_uhQfb3bW_KMvuieAn4HtvhvcTv8cXG-ag37sB9c5vW-3Y8Ne6g7_O721uj_cttrZ5m44uv0k7IWvngGZIpsm</recordid><startdate>20020101</startdate><enddate>20020101</enddate><creator>Onishi, Hideya</creator><creator>Morisaki, Takashi</creator><creator>Kuga, Hirotaka</creator><creator>Katano, Mitsuo</creator><creator>Doi, Fukashi</creator><creator>Uchiyama, Akihiko</creator><creator>Sugitani, Atsushi</creator><creator>Wada, Junji</creator><creator>Chijiiwa, Kazuo</creator><creator>Tanaka, Masao</creator><general>Informa UK Ltd</general><general>Taylor & Francis</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20020101</creationdate><title>A LARGE QUANTITY OF CD3− CD19− CD16− LYMPHOCYTES IN MALIGNANT PLEURAL EFFUSION FROM A PATIENT WITH RECURRENT CHOLANGIO CELL CARCINOMA</title><author>Onishi, Hideya ; Morisaki, Takashi ; Kuga, Hirotaka ; Katano, Mitsuo ; Doi, Fukashi ; Uchiyama, Akihiko ; Sugitani, Atsushi ; Wada, Junji ; Chijiiwa, Kazuo ; Tanaka, Masao</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c386t-1d3c84bfee1d05d02283f23a271f0c917af40280f19dd3d1d1a674479ee72d2a3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2002</creationdate><topic>Antigens, CD19 - metabolism</topic><topic>CD3 Complex - metabolism</topic><topic>Cholangiocarcinoma - immunology</topic><topic>Cholangiocarcinoma - therapy</topic><topic>Humans</topic><topic>Immunotherapy, Adoptive</topic><topic>In Vitro Techniques</topic><topic>Interferon-gamma - biosynthesis</topic><topic>Lymphocytes, Tumor-Infiltrating - immunology</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Neoplasm Recurrence, Local - immunology</topic><topic>Neoplasm Recurrence, Local - therapy</topic><topic>Picibanil - pharmacology</topic><topic>Pleural Effusion, Malignant - immunology</topic><topic>Pleural Effusion, Malignant - therapy</topic><topic>Receptors, IgG - metabolism</topic><topic>T-Lymphocytes - immunology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Onishi, Hideya</creatorcontrib><creatorcontrib>Morisaki, Takashi</creatorcontrib><creatorcontrib>Kuga, Hirotaka</creatorcontrib><creatorcontrib>Katano, Mitsuo</creatorcontrib><creatorcontrib>Doi, Fukashi</creatorcontrib><creatorcontrib>Uchiyama, Akihiko</creatorcontrib><creatorcontrib>Sugitani, Atsushi</creatorcontrib><creatorcontrib>Wada, Junji</creatorcontrib><creatorcontrib>Chijiiwa, Kazuo</creatorcontrib><creatorcontrib>Tanaka, Masao</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Immunological investigations</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Onishi, Hideya</au><au>Morisaki, Takashi</au><au>Kuga, Hirotaka</au><au>Katano, Mitsuo</au><au>Doi, Fukashi</au><au>Uchiyama, Akihiko</au><au>Sugitani, Atsushi</au><au>Wada, Junji</au><au>Chijiiwa, Kazuo</au><au>Tanaka, Masao</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>A LARGE QUANTITY OF CD3− CD19− CD16− LYMPHOCYTES IN MALIGNANT PLEURAL EFFUSION FROM A PATIENT WITH RECURRENT CHOLANGIO CELL CARCINOMA</atitle><jtitle>Immunological investigations</jtitle><addtitle>Immunol Invest</addtitle><date>2002-01-01</date><risdate>2002</risdate><volume>31</volume><issue>2</issue><spage>121</spage><epage>135</epage><pages>121-135</pages><issn>0882-0139</issn><eissn>1532-4311</eissn><abstract>Tumor infiltrating lymphocytes (TILs) are candidates for adoptive cellular immunotherapy. Here we report on a patient whose TILs presented unusual lymphocyte antigens. Pleural effusions were collected from a 47-year-old man with recurrent cholangio cell carcinoma and malignant effusion. Effusion- associated lymphocytes (EALs) were separated by Ficoll-Hypaque gradient, and the EAL phenotype was determined by flow cytometry. The percentage of positive cells was determined for each lymphocyte-related differentiation antigen. The percentages of CD3+, CD19+, and CD16+ lymphocyte subpopulations among EALs were 20%, 7%, and 3%, respectively. Nearly 70% of EALs were CD3− CD19− CD56− CD16−cells. The phenotypes of peripheral blood lymphocytes (PBLs) collected simultaneously from the patient's peripheral blood were CD3+ (52%), CD19+ (20%), and CD16+ (20%).When EALs were cultured in medium without pleural effusion, T cell-related antigens, but not B cell- or natural killer (NK) cell-related antigens, were newly expressed on EALs, and this expression reached a plateau after 48 h in culture. The proportions of CD3+, CD19+, and CD16+ cells were 69%, 7%, and 3%, respectively. However, when EALs were cultured in medium with pleural effusion, increased expression of T cell-related antigens was not observed; the proportions of CD3+, CD19+, and CD16+ cells were 16%, 6%, and 1%, respectively. Neither total cell numbers nor cellular viability of EALs changed significantly after in-vitro culture, suggesting that significant proliferation or death of EALs did not occur during the culture period. Co-culture of the patient's PBLs with autologous pleural effusion for 96 h did not alter the expression of lymphocyte-related antigens on the PBLs. These results indicate that expression of T cell-related antigens, but not B cell- or NK cell-related antigens, on EALs was blocked temporarily by the malignant pleural effusion. This is the first report concerning the existence of a large quantity of unclassified lymphocytes in which the T cell-related antigens were reversibly masked in the malignant pleural effusion.</abstract><cop>England</cop><pub>Informa UK Ltd</pub><pmid>12148948</pmid><doi>10.1081/IMM-120004803</doi><tpages>15</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0882-0139 |
ispartof | Immunological investigations, 2002-01, Vol.31 (2), p.121-135 |
issn | 0882-0139 1532-4311 |
language | eng |
recordid | cdi_pubmed_primary_12148948 |
source | Taylor and Francis:Jisc Collections:Taylor and Francis Read and Publish Agreement 2024-2025:Medical Collection (Reading list) |
subjects | Antigens, CD19 - metabolism CD3 Complex - metabolism Cholangiocarcinoma - immunology Cholangiocarcinoma - therapy Humans Immunotherapy, Adoptive In Vitro Techniques Interferon-gamma - biosynthesis Lymphocytes, Tumor-Infiltrating - immunology Male Middle Aged Neoplasm Recurrence, Local - immunology Neoplasm Recurrence, Local - therapy Picibanil - pharmacology Pleural Effusion, Malignant - immunology Pleural Effusion, Malignant - therapy Receptors, IgG - metabolism T-Lymphocytes - immunology |
title | A LARGE QUANTITY OF CD3− CD19− CD16− LYMPHOCYTES IN MALIGNANT PLEURAL EFFUSION FROM A PATIENT WITH RECURRENT CHOLANGIO CELL CARCINOMA |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-29T12%3A22%3A22IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=A%20LARGE%20QUANTITY%20OF%20CD3%E2%88%92%20CD19%E2%88%92%20CD16%E2%88%92%20LYMPHOCYTES%20IN%20MALIGNANT%20PLEURAL%20EFFUSION%20FROM%20A%20PATIENT%20WITH%20RECURRENT%20CHOLANGIO%20CELL%20CARCINOMA&rft.jtitle=Immunological%20investigations&rft.au=Onishi,%20Hideya&rft.date=2002-01-01&rft.volume=31&rft.issue=2&rft.spage=121&rft.epage=135&rft.pages=121-135&rft.issn=0882-0139&rft.eissn=1532-4311&rft_id=info:doi/10.1081/IMM-120004803&rft_dat=%3Cproquest_pubme%3E71955780%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c386t-1d3c84bfee1d05d02283f23a271f0c917af40280f19dd3d1d1a674479ee72d2a3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=71955780&rft_id=info:pmid/12148948&rfr_iscdi=true |